Medtronic PLC vs Symbotic Inc — how do they compare? Medtronic PLC trades at $82.67 (market cap $106.61B), while Symbotic Inc trades at $42.41 (market cap $5.19B). The key difference: Medtronic PLC is far larger — about 20.5× Symbotic Inc's market cap, and Medtronic PLC pays a 3.46% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| MDT | SYM | |
|---|---|---|
Market Cap | $106.61B | $5.19B |
Sector | Health | Technology |
52-Week High | $105.35 | $87.30 |
52-Week Low | $73.75 | $38.57 |
Enterprise Value | $125.36B | $3.18B |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Symbotic (SYM) trades at $40.83, down 1.02% recently, with a bearish technical signal and key support at $40. The company reported revenue of $2.25 billion in 2025 but a net loss of $16.94 million, though gross margins improved to 20.43%. Recent news highlights its acquisition of ARMS Innovations and upcoming Q3 2026 earnings on August 5, 2026, amid growing interest in warehouse automation.
Analyst consensus is bullish with a $57.50 price target, but risks include persistent net losses, high EV/EBITDA of 219.3, and competitive pressures. The stock offers growth potential from AI-driven warehouse automation demand, yet profitability challenges and market volatility pose significant headwinds for investors.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →